The European Union has granted CE Mark approval to Cordis, a Johnson & Johnson unit, to market a drug-coated stent for the treatment of patients with diabetes. The Cypher Select Plus Sirolimus-eluting coronary stent features the CYPH2ONIC hydrophilic coating technology that offers more flexibility to doctors in moving into hard-to-navigate coronary arteries.

Related Summaries